Literature DB >> 23205127

Tagged and untagged TRAIL show different activity against tumor cells.

Kunpeng Zhao1, Yan'ge Wang, Xueyin Wang, Yugang Wang, Yuanfang Ma.   

Abstract

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) is a novel cytotoxic ligand belonging to the TNF superfamily which is currently being developed as a cancer therapeutic drug. Here, we observed the different functions of recombinant TRAIL protein with a foreign protein label and non-labeled TRAIL. We used a prokaryotic expression system to prepare two different versions of the extracellular TRAIL 114-281aa protein: TRAIL-HS, a protein modified with 6xHis-Tag and S-Tag; and TRAIL-FT, which had no foreign protein. The proteins were purified using Ni-NTA chromatography (TRAIL-HS) and cation ion-exchange column chromatography (TRAIL-FT) and identified by SDS-PAGE and western blot analysis. We compared the abilities of the proteins to bind to death receptor 5 (DR5) by ELISA and to induce apoptosis in a normal liver cell line (Chang liver) and a human T-lymphocyte leukemia cell line (Jurkat) by MTT assay, GR staining and FACS. The results indicate that the biological functions of TRAIL-FT were superior to those of TRAIL-HS in binding and the induction of apoptosis, and may be useful to further the development and applications of TRAIL.

Entities:  

Year:  2012        PMID: 23205127      PMCID: PMC3506756          DOI: 10.3892/ol.2012.908

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  11 in total

1.  Improvement of expression level and bioactivity of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) by a novel zinc ion feeding strategy.

Authors:  Ai-You Sun; Ya-Ling Shen; Ji-Cheng Yin; Hong Zhang; Ya-Nan Tang; Dong-Zhi Wei
Journal:  Biotechnol Lett       Date:  2006-06-24       Impact factor: 2.461

2.  Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Authors:  H Walczak; R E Miller; K Ariail; B Gliniak; T S Griffith; M Kubin; W Chin; J Jones; A Woodward; T Le; C Smith; P Smolak; R G Goodwin; C T Rauch; J C Schuh; D H Lynch
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

3.  Identification and characterization of a new member of the TNF family that induces apoptosis.

Authors:  S R Wiley; K Schooley; P J Smolak; W S Din; C P Huang; J K Nicholl; G R Sutherland; T D Smith; C Rauch; C A Smith
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

Review 4.  TRAIL and its receptors as targets for cancer therapy.

Authors:  Hideo Yagita; Kazuyoshi Takeda; Yoshihiro Hayakawa; Mark J Smyth; Ko Okumura
Journal:  Cancer Sci       Date:  2004-10       Impact factor: 6.716

5.  Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis.

Authors:  M Leverkus; H Walczak; A McLellan; H W Fries; G Terbeck; E B Bröcker; E Kämpgen
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

6.  Safety and antitumor activity of recombinant soluble Apo2 ligand.

Authors:  A Ashkenazi; R C Pai; S Fong; S Leung; D A Lawrence; S A Marsters; C Blackie; L Chang; A E McMurtrey; A Hebert; L DeForge; I L Koumenis; D Lewis; L Harris; J Bussiere; H Koeppen; Z Shahrokh; R H Schwall
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 7.  TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.

Authors:  Erika Cretney; Anil Shanker; Hideo Yagita; Mark J Smyth; Thomas J Sayers
Journal:  Immunol Cell Biol       Date:  2006-02       Impact factor: 5.126

8.  Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand.

Authors:  J Z Qin; P Bacon; V Chaturvedi; B J Nickoloff
Journal:  J Invest Dermatol       Date:  2001-10       Impact factor: 8.551

9.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Authors:  D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

Review 10.  TRAIL as a target in anti-cancer therapy.

Authors:  Gen Sheng Wu
Journal:  Cancer Lett       Date:  2009-03-18       Impact factor: 8.679

View more
  2 in total

Review 1.  Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.

Authors:  Anna-Laura Kretz; Silvia von Karstedt; Andreas Hillenbrand; Doris Henne-Bruns; Uwe Knippschild; Anna Trauzold; Johannes Lemke
Journal:  Cancers (Basel)       Date:  2018-03-18       Impact factor: 6.639

2.  Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.

Authors:  Maximilian Richter; Roma Yumul; Kamola Saydaminova; Hongjie Wang; Michael Gough; Audrey Baldessari; Roberto Cattaneo; Frank Lee; Chung-Huei Katherine Wang; Haishan Jang; Anne Astier; Ajay Gopal; Darrick Carter; André Lieber
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.